Tarceva News and Research

RSS
Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774.
Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

Hana Biosciences second-quarter net loss decreases to $6.3 million

Hana Biosciences second-quarter net loss decreases to $6.3 million

Synta second-quarter net loss increases to $9.1 million

Synta second-quarter net loss increases to $9.1 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

AVEO second-quarter total revenues increase to $15.6 million

AVEO second-quarter total revenues increase to $15.6 million

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

OSI Pharmaceuticals terminates Offer to Purchase 2% Convertible Senior Subordinated Notes due 2025

OSI Pharmaceuticals terminates Offer to Purchase 2% Convertible Senior Subordinated Notes due 2025

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Erlotinib can reduce lung cancer death by 26% : Study

Erlotinib can reduce lung cancer death by 26% : Study

ArQule, Daiichi Sankyo present positive data from Phase 2 combination ARQ 197 trial for lung cancer at ASCO

ArQule, Daiichi Sankyo present positive data from Phase 2 combination ARQ 197 trial for lung cancer at ASCO

OSI Pharmaceuticals' 2% Senior Subordinated Notes to remain convertible through July 6, 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes to remain convertible through July 6, 2010

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Astellas Pharma, OSI Pharmaceuticals sign definitive merger agreement

Astellas Pharma, OSI Pharmaceuticals sign definitive merger agreement